1. Home
  2. CMPS vs PRME Comparison

CMPS vs PRME Comparison

Compare CMPS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$6.95

Market Cap

598.7M

Sector

Health Care

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$4.26

Market Cap

601.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPS
PRME
Founded
2020
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
598.7M
601.1M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
CMPS
PRME
Price
$6.95
$4.26
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$16.43
$9.31
AVG Volume (30 Days)
1.6M
3.9M
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,977,000.00
Revenue This Year
N/A
$111.80
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
647.13
52 Week Low
$2.25
$1.11
52 Week High
$7.09
$6.94

Technical Indicators

Market Signals
Indicator
CMPS
PRME
Relative Strength Index (RSI) 69.32 53.84
Support Level $4.90 $3.95
Resistance Level $5.57 $4.42
Average True Range (ATR) 0.38 0.30
MACD 0.21 0.13
Stochastic Oscillator 90.09 84.91

Price Performance

Historical Comparison
CMPS
PRME

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Share on Social Networks: